Role of antibodies to human papillomavirus 16 in prostate cancer: A seroscreening by peptide microarray
Evidence is accumulating in estimating the potential role of human papillomavirus infection in prostate carcinogenesis. However, the results remain inconclusive. We measured the serostatus of antibodies to one of the high-risk human papillomaviruses, human papillomavirus 16, with a newly developed p...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2017-05-01
|
| Series: | Tumor Biology |
| Online Access: | https://doi.org/10.1177/1010428317698371 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849415105082556416 |
|---|---|
| author | Xiaojun Zhao Zheng Zhou Ye Chen Wen Chen Hongwei Ma Jinxian Pu |
| author_facet | Xiaojun Zhao Zheng Zhou Ye Chen Wen Chen Hongwei Ma Jinxian Pu |
| author_sort | Xiaojun Zhao |
| collection | DOAJ |
| description | Evidence is accumulating in estimating the potential role of human papillomavirus infection in prostate carcinogenesis. However, the results remain inconclusive. We measured the serostatus of antibodies to one of the high-risk human papillomaviruses, human papillomavirus 16, with a newly developed peptide microarray. Serum samples were collected from 75 untreated prostate cancer patients, along with 80 control subjects. We identified 12 peptides with significant differences in prostate cancer samples from all 241 peptides derived from human papillomavirus 16. Our results showed human papillomavirus 16 infection in 64.0% of prostate cancer serum samples, which is significantly different compared with the controls ( p < 0.01) because only 17.5% of the control serum was considered seropositive. The area under the receiver operator characteristic curve was 0.793 (95% confidence interval 0.721–0.864), indicating that the new microarray technique may have diagnostic value. The results showed an association between serological evidence for human papillomavirus 16 infection and risk of prostate cancer. The different serostatus of antibodies in the two subgroups indicated that human papillomavirus 16 infection might occur and play a potential role of progression in a minority of prostate cancer. |
| format | Article |
| id | doaj-art-629b73eb8dec427bb3bc79d1cf844a49 |
| institution | Kabale University |
| issn | 1423-0380 |
| language | English |
| publishDate | 2017-05-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Tumor Biology |
| spelling | doaj-art-629b73eb8dec427bb3bc79d1cf844a492025-08-20T03:33:38ZengSAGE PublishingTumor Biology1423-03802017-05-013910.1177/1010428317698371Role of antibodies to human papillomavirus 16 in prostate cancer: A seroscreening by peptide microarrayXiaojun Zhao0Zheng Zhou1Ye Chen2Wen Chen3Hongwei Ma4Jinxian Pu5Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, P.R. ChinaDepartment of Urology, The First Affiliated Hospital of Soochow University, Suzhou, P.R. ChinaDepartment of Urology, The First Affiliated Hospital of Soochow University, Suzhou, P.R. ChinaSuzhou SJ Biomaterials Co., Ltd, Suzhou, P.R. ChinaNano-Bio-Chem Centre, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou, P.R. ChinaDepartment of Urology, The First Affiliated Hospital of Soochow University, Suzhou, P.R. ChinaEvidence is accumulating in estimating the potential role of human papillomavirus infection in prostate carcinogenesis. However, the results remain inconclusive. We measured the serostatus of antibodies to one of the high-risk human papillomaviruses, human papillomavirus 16, with a newly developed peptide microarray. Serum samples were collected from 75 untreated prostate cancer patients, along with 80 control subjects. We identified 12 peptides with significant differences in prostate cancer samples from all 241 peptides derived from human papillomavirus 16. Our results showed human papillomavirus 16 infection in 64.0% of prostate cancer serum samples, which is significantly different compared with the controls ( p < 0.01) because only 17.5% of the control serum was considered seropositive. The area under the receiver operator characteristic curve was 0.793 (95% confidence interval 0.721–0.864), indicating that the new microarray technique may have diagnostic value. The results showed an association between serological evidence for human papillomavirus 16 infection and risk of prostate cancer. The different serostatus of antibodies in the two subgroups indicated that human papillomavirus 16 infection might occur and play a potential role of progression in a minority of prostate cancer.https://doi.org/10.1177/1010428317698371 |
| spellingShingle | Xiaojun Zhao Zheng Zhou Ye Chen Wen Chen Hongwei Ma Jinxian Pu Role of antibodies to human papillomavirus 16 in prostate cancer: A seroscreening by peptide microarray Tumor Biology |
| title | Role of antibodies to human papillomavirus 16 in prostate cancer: A seroscreening by peptide microarray |
| title_full | Role of antibodies to human papillomavirus 16 in prostate cancer: A seroscreening by peptide microarray |
| title_fullStr | Role of antibodies to human papillomavirus 16 in prostate cancer: A seroscreening by peptide microarray |
| title_full_unstemmed | Role of antibodies to human papillomavirus 16 in prostate cancer: A seroscreening by peptide microarray |
| title_short | Role of antibodies to human papillomavirus 16 in prostate cancer: A seroscreening by peptide microarray |
| title_sort | role of antibodies to human papillomavirus 16 in prostate cancer a seroscreening by peptide microarray |
| url | https://doi.org/10.1177/1010428317698371 |
| work_keys_str_mv | AT xiaojunzhao roleofantibodiestohumanpapillomavirus16inprostatecanceraseroscreeningbypeptidemicroarray AT zhengzhou roleofantibodiestohumanpapillomavirus16inprostatecanceraseroscreeningbypeptidemicroarray AT yechen roleofantibodiestohumanpapillomavirus16inprostatecanceraseroscreeningbypeptidemicroarray AT wenchen roleofantibodiestohumanpapillomavirus16inprostatecanceraseroscreeningbypeptidemicroarray AT hongweima roleofantibodiestohumanpapillomavirus16inprostatecanceraseroscreeningbypeptidemicroarray AT jinxianpu roleofantibodiestohumanpapillomavirus16inprostatecanceraseroscreeningbypeptidemicroarray |